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Examining Fluoxetine Treatment for Selective Mutism in Children
Selective mutism (SM), previously referred to as elective mutism, is a disorder that is
classified by the refusal or failure to talk in one or more social situations, despite the
mental capacity and physical ability to comprehend and participate in spoken language
(Black & Uhde, 1994). While this disorder can be extremely debilitating to the children
affected, there is little known about this disorder. This is largely because there were no
studies describing etiology, history, characteristics and treatment of children with SM until
around 1993 (Dummit, Klein, Tancer, Asche, & Martin, 1996). This disorder can negatively
impact the ability to reach childhood developmental milestones, especially socially and
academically, because of the lack of verbal communication. Because of these devastating
effects in early childhood that can occur and shape the rest of a child’s education and social
experiences, it is very important to learn more about this disorder and the treatment
options. One treatment option has been to administer Fluoxetine, a selective serotonin
reuptake inhibitor often used as an antidepressant or to help with anxiety symptoms. This
paper will provide a review of the evidence of Fluoxetine as a treatment for selective
mutism, and then critique the evidence in comparison with other treatment options. A
short overview of etiology and background will be provided, followed by an overview of
treatments available for SM and an explanation of fluoxetine treatment. The literature
regarding fluoxetine treatment will then be critiqued. The side effects of fluoxetine in
comparison to other pharmacotherapy options will be discussed and finally, other nonpharmacotherapy options will be examined.
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Etiology of Selective Mutism
Selective mutism is characterized by a failure to speak in social situations or respond
when spoken to. The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM–5;
American Psychiatric Association, 2013) states that this failure to speak must interfere
with communication in a variety of settings (social, academic) for at least one month, and
that it cannot be due to a lack of knowledge of spoken language. This disorder is rare, with
a prevalence of between .03 – 1%. It usually begins before five years of age, and persistence
varies with each individual. Some children ‘outgrow’ it with time, and others require
clinical intervention in order to be successful in academic or social environments. In many
cases, the symptoms of SM may disappear, but symptoms of another anxiety disorder may
still exist, often social anxiety or social phobia (American Psychiatric Association, 2013).
The causes are largely unknown; some parenting factors may play a role in development,
such as demonstrating social inhibition or overprotective parenting, as well as negative
affectivity of the child, or other possible language difficulties. Most frequently, other
anxiety disorders or oppositional defiant disorder have been known to be comorbid with
selective mutism. Overall, there is little conclusive information known about the cause and
course of this disorder, and more research needs to be done in order to gain more insight
about the disorder itself and how to treat it.
Treatments Available
Many different kinds of psychosocial and pharmacological interventions have been
utilized for the treatment of selective mutism in children. Psychosocial interventions have
included behavioral therapy, group therapy, family therapy, and intensive programs
focusing on multimodal psychosocial treatment (Manassis, 2009). Many case reports have
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studied these types of treatment, as well as a few large-scale studies, with findings that
support these treatment options when administered appropriately (Harvey & Milne, 1998;
Wright et al., 1995; Manassis, 2009). There is more data supporting behavioral and
multimodal treatments because of the larger research base for these, and cognitive
behavioral therapy is thought to be a positive treatment option for children who are older
than 8 years (Manassis, 2009). Generally these types of treatments are the first ones tried
when treating children with selective mutism.
There has also been research regarding pharmacotherapy for selective mutism in
children, most frequently involving SSRIs or other medications known to be helpful in
treating social phobia, a closely related disorder (Dow, Sonies, Scheib, & Moss, 1996). One
type of MAOI medication used as treatment for SM is phenelzine. This drug seems to have
some positive treatment effects, however, there are significant food, dietary, and drug
interactions and restrictions associated with its use, making it a less-than-ideal option for
children (Kaakeh & Stumpf, 2008). Common SSRIs used include fluvoxamine, sertraline,
paroxetine, and fluoxetine. The first three listed have very few studies involving them as
treatment at all, and the studies that are available lack standardization, randomization, and
have had very small sample sizes. These factors are part of the reason there is a very small
body of research findings regarding the use of these drugs as treatment. The most
frequently administered and studied pharmacotherapy for selective mutism is fluoxetine.
Fluoxetine Treatment Overview
Pharmacological treatment of selective mutism often includes the administration of
selective serotonin reuptake inhibitor (SSRI) medications because of their effects on closely
related mood and anxiety disorders (Dow, Sonies, Scheib, & Moss, 1996). The most
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commonly studied SSRI in the treatment of SM is fluoxetine, most likely because of the high
efficacy it has showed when treating social phobia (Kaakeh & Stumpf, 2008). Fluoxetine
has been regarded as an ideal medication for children, largely because of the minimal side
effects associated with it, including markedly less sedation affects in comparison to other
SSRIs (Harvey & Milne, 1998). In addition, the dosage of the drug allows for a variety of
different titration methods and flexibility when being administered to children, which is
extremely important for countering side-effects the drug may have in clinical studies. Many
studies begin with a low dosage and slowly increase the medication, depending on the
overall effects of the drug with each individual child. If negative side effects occur, dosage is
lessened.
Literature Review
There are many literature reviews discussing studies of fluoxetine treatment in children
with selective mutism, many of them agreeing of this as a valid treatment option. However,
considering limited information is known about the efficacy of any drug therapy for this
disorder, pharmacological treatment should usually be considered as a secondary
treatment when psychotherapy alone has failed (Kaakeh & Stumpf, 2008). When
pharmacological intervention is necessary, fluoxetine has more evidence of efficacy than
other medications, likely because it has been studied more widely (Manassis, 2009). In
many studies, dosages should start low and increase gradually with close monitoring. This
is because it is easier to control positive and negative effects of the drug for the children it
is being tested in. It is noted in some review articles of case studies that there are reports of
‘positive effects’ of fluoxetine therapy, but minimal detail or explanation is given in these
reports (Dow et al., 1996). This is important to note because it illustrates the necessity for
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future research on this topic in order to understand if it is a safe and effective treatment
option for children.
The bulk of information on fluoxetine treatment for children with SM has been reported
through case studies. Though low in efficacy and generalizability, they provide the
groundwork needed for further research into this treatment. One of the most frequently
cited case reports studied a 4 year old female named Leah, with pervasive symptoms of
selective mutism that were not improved through an intensive preschool program focused
on diagnosis and intervention of child disorders (Wright, Cuccaro, Leonhardt, Kendall, &
Anderson, 1995). After the first five days of fluoxetine treatment at a beginning dose of
4mg/day, Leah began to increase verbal communication in some environments. At the end
of twenty days of treatment and with an increased dosage of 8mg/day, Leah was talking at
an age-appropriate level in all settings.
Other case studies report similar findings of positive improvement regarding verbal
communication increases with varying time frames of the children responding to fluoxetine
(Harvey & Milne, 1998; Silveira, Jainer, & Bates, 2004). All case studies in this review
administered fluoxetine treatment only after participant’s symptoms were not improved
through other interventions, such as behavior therapy, intensive programs, and
psychotherapy. Detailed accounts of these individual case studies are important for piloting
future experiments of fluoxetine treatment for children with selective mutism.
Manassis and Tannock, working with many other researchers, have published multiple
sources regarding selective mutism and fluoxetine treatment. A correlational study they
published examines many language, cognitive, and anxiety symptoms in comparison with
children who have a diagnosis of selective mutism and/or other anxiety disorders
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(Manassis et al., 2007). The results from this study were used as the basis for a study that
utilized a portion of the same participants for a quasi-experimental design study comparing
treatments for selective mutism (Manassis & Tannock, 2008). All participants received
school interventions for an amount of time, and then slightly more than half also began
receiving SSRIs. All but two participants were administered fluoxetine at dosage
appropriate on an individual basis. The children who were receiving medication treatment
showed significantly more improvement of symptoms when compared to those who were
not receiving medication. While it cannot be determined what the impact of medication
alone is for selective mutism symptoms, the results of this study suggest some significant
positive impact of administering medication and noticing a positive change in symptoms.
Finally, there are only two well known experimental design studies published at this
time that examine the impact of fluoxetine treatment on children with selective mutism.
The first administered fluoxetine to a randomly assigned group of participants on a titrated
schedule while receiving parental and teacher reports of symptoms over approximately 14
weeks of the school year (Black & Uhde, 1994). The second study administered fluoxetine
on a titration schedule for 9 weeks while measuring progress through weekly visits with
the treating psychiatrist (Dummit et al., 1996). Each of these experiments found that
fluoxetine was well tolerated in the children and seemed safe for the short amount of time
that it was monitored. However, Black & Uhde found fluoxetine to be of limited usefulness,
because their findings did not reach significant differences when compared to the control
group regarding reports of parents and teachers (1994). Dummit et al. found significant
improvement in symptoms, but the study did not control for other factors, it was difficult to
determine what role the medication played in this improvement (1996). In each study,
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minimal side effects were reported and symptoms for each individual seemed to improve
for the better.
Critique
The research of fluoxetine treatment for children with selective mutism is not
extensive, but is able to begin the discussion on this topic. The research at this time does
not allow for a conclusion about the effectiveness or efficacy of fluoxetine treatment in
children with SM to be determined. Some of the research has illustrated a correlation
between administering SSRI medication and decreasing symptomology of selective mutism
(Manassis & Tannock, 2008). However, with a lack of randomization and controlling for
confounding variables including the impact of other treatments administered at the same
time, this information should not be taken as concrete evidence.
The bulk of information on this topic is derived from case studies involving one or two
individuals. While case studies are beneficial and important to providing some insight onto
a treatment option, they are extremely limited in offering information about a treatment
option as a whole. While a case report can illustrate that a treatment option worked for an
individual, such as with Leah who was discussed earlier (Wright et al., 1995), the
information is not generalizable to other individuals with similar problems. Case studies
simply do not provide enough information to safely determine if a treatment works or not.
Slightly better in being able to determine outcomes of a specific treatment plan are
quasi-experimental studies. Two of these studies have been done regarding selective
mutism, with one of them focusing specifically on intervention options to help symptoms of
the disorder (Manassis et al., 2007; Manassis & Tannock, 2008). A correlation between
symptoms of selective mutism and school intervention and/or medicinal intervention was
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found. Children who were administered medication, including fluoxetine, were significantly
improved in symptoms by the end of the study (Manassis & Tannock, 2008). However,
because there was no randomization of participants into different groups, only a
correlation between a decrease in SM symptoms and administration of SSRI medication can
be determined at this time. As correlation does not equal causation, the only conclusion
that can be made from this study is the negative correlation between administering SSRIs
and decreasing symptoms; no information on the cause of this relationship can be
determined.
In addition, only two randomized control studies have been published at this time, with
combined participants totaling 36 children. This alone is not consistent with the amount of
participants necessary to determine a treatment’s efficacy within a controlled environment
or the effectiveness for children in natural environments. The low participant numbers and
the experimental designs of the information that is currently available regarding fluoxetine
treatment for children with SM create significant limitations, and are a large reason that no
concrete conclusions can be drawn about the efficacy or effectiveness of treatment.
As stated, essentially all published information on fluoxetine treatment uses it as a
secondary treatment plan. Reports vary on whether the initially administered treatment is
continued or stopped when pharmacological treatment begins. Black & Uhde explicitly
excluded participants who required other treatment during the time of the experiment,
making their study one of the only ones that attempted to control for interference of other
treatment while studying the effects of medication alone. Dummit et al. also controlled for
confounding variables associated with other treatment by administering psychotherapy to
any participants who had not previously received it and excluding those who responded to
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it alone. Without controlling for the effects of other treatments while examining the
treatment at hand, confounding variables can skew the data that is found from the study.
While the low numbers and overall design of the studies examining fluoxetine
treatment for SM are weaknesses of the research on this topic as a whole, there are some
strengths within this research body. Fluoxetine has been regarded as a superior treatment
option within pharmacotherapy as a whole because of the minimal side effects when
compared to other types of SSRI or pharmacotherapy options as a whole (Harvey & Milne,
1998). Additionally, as previously stated, Fluoxetine is the most frequently studied SSRI
type of medication when administered to children with selective mutism diagnosis or
symptoms (Kaakeh & Stumpf, 2008). This being said, there is more information known
about this specific pharmacological treatment than there is about any other for selective
mutism.
There also seems to be evidence that fluoxetine should not be considered a primary
treatment option. All of the individuals in the case studies mentioned were initially treated
with differing kinds of behavioral therapy or intensive psychotherapy treatment programs
before being administered fluoxetine as treatment (Harvey & Milne, 1998; Silveira et al.,
2004; Wright et al., 1995). Review articles also note that this treatment option should be
considered for children with severe selective mutism that has been unresponsive to other
types of interventions previously administered (Manassis, 2009). This consensus of
fluoxetine as a secondary treatment option is a concrete strength of this body of research.
In addition, there is a general consensus among all published studies that fluoxetine
works in improving symptoms of selective mutism. While no concrete conclusions of
efficacy or effectiveness can be drawn from this data, it gives a positive outlook on this

Fluoxetine for Selective Mutism in Children

11

treatment option. It is the hope that vast future research will continue, specifically research
that addresses the weaknesses of this body of research as a whole. More randomized,
controlled experiments should be administered with larger sample sizes in order to
effectively analyze the outcomes of fluoxetine treatment for children who are administered
the drug for treatment of selective mutism. In these experiments, comparisons with other
SSRIs, pharmacotherapy options, and psychological interventions should be examined
separately in order to determine the best available treatment for children affected by SM.
In addition, controls for co-morbidity, sex differences, and environmental factors need to
be studied with the administration of fluoxetine to determine if this option is valid for
certain populations or the generalized public as a whole.
Conclusion
Selective mutism is a debilitating childhood disorder that impacts developmental
and academic milestones, as well as social relationships within the children who are
affected. As illustrated through the studies cited in this paper, the information that is
available largely supports the theory that fluoxetine has the potential to be a successful
treatment for children with selective mutism and that there are few side-effects when
administered correctly, but more information and research is necessary to be able to
determine concrete conclusions. The literature suggests a consensus that this treatment
option should be considered secondary, as providing young children with any type of
pharmacological psychiatric treatment is often controversial and can have many negative
impacts. In addition, there have been studies proving it’s efficacy as well as it’s
effectiveness in treating symptoms of SM, but most of the literature available focuses on
small sample sizes and short periods of assessment. For these reasons, the data is not
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generalizable or significant enough to determine if this is a truly valid treatment option for
children.
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